Episode 202: Helen Branswell on the pandemic, plus the next FDA debate & the perks of being a CEO

Are Covid-19 vaccines a sustainable business? Was Aduhelm an aberration? And what comes after Omicron? Senior writer Helen Branswell joins us to discuss the latest twists in the pandemic, including rising case counts, next-generation vaccines, and the latest data from pediatric trials. We also dive into the latest news in the life sciences, including Moderna's grand ambitions, Al Sandrock's new job, and the next big FDA debate.